Vaccines,
Год журнала:
2024,
Номер
12(2), С. 156 - 156
Опубликована: Фев. 2, 2024
Contagious
agalactia
(CA)
is
a
serious
multietiological
disease
whose
classic
etiological
agent
Mycoplasma
agalactiae
and
which
causes
high
morbidity
mortality
rates
in
infected
herds.
CA
classified
as
notifiable
by
the
World
Organization
for
Animal
Health
due
to
its
significant
worldwide
economic
impact
on
livestock,
primarily
involving
goat
sheep
farms.
The
emergence
of
atypical
symptoms
strains
M.
wildlife
ungulates
reestablishes
highly
plastic
genome
also
great
epidemiological
significance.
Antimicrobial
therapy
main
form
control,
although
several
factors,
such
intrinsic
antibiotic
resistance
selection
resistant
strains,
must
be
considered.
Available
vaccines
are
few
mostly
inefficient.
virulence
pathogenicity
mechanisms
mainly
rely
surface
molecules
that
have
direct
contact
with
host.
Because
this,
they
essential
development
vaccines.
This
review
highlights
currently
available
their
limitations
new
vaccine
possibilities,
especially
considering
challenge
antigenic
variation
dynamic
this
microorganism.
Immunosenescence
increases
the
risk
and
severity
of
diseases
in
elderly
individuals
leads
to
impaired
vaccine-induced
immunity.
With
aging
global
population
emerging
epidemics,
developing
adjuvants
vaccines
for
improve
their
immune
protection
is
pivotal
healthy
worldwide.
Deepening
our
understanding
role
immunosenescence
vaccine
efficacy
could
accelerate
research
focused
on
optimizing
delivery
individuals.
In
this
review,
we
analyzed
characteristics
at
cellular
molecular
levels.
Strategies
vaccination
potency
are
summarized,
including
increasing
antigen
dose,
preparing
multivalent
vaccines,
adding
appropriate
adjuvants,
inhibiting
chronic
inflammation,
immunosenescence.
We
hope
that
review
can
provide
a
new
findings
with
regards
impacts
vaccine-mediated
inspire
development
individualized
Signal Transduction and Targeted Therapy,
Год журнала:
2025,
Номер
10(1)
Опубликована: Март 5, 2025
The
successful
approval
of
peptide-based
drugs
can
be
attributed
to
a
collaborative
effort
across
multiple
disciplines.
integration
novel
drug
design
and
synthesis
techniques,
display
library
technology,
delivery
systems,
bioengineering
advancements,
artificial
intelligence
have
significantly
expedited
the
development
groundbreaking
drugs,
effectively
addressing
obstacles
associated
with
their
character,
such
as
rapid
clearance
degradation,
necessitating
subcutaneous
injection
leading
increasing
patient
discomfort,
ultimately
advancing
translational
research
efforts.
Peptides
are
presently
employed
in
management
diagnosis
diverse
array
medical
conditions,
diabetes
mellitus,
weight
loss,
oncology,
rare
diseases,
additionally
garnering
interest
facilitating
targeted
platforms
advancement
vaccines.
This
paper
provides
an
overview
present
market
clinical
trial
progress
therapeutics,
platforms,
It
examines
key
areas
through
literature
analysis
emphasizes
structural
modification
principles
well
recent
advancements
screening,
design,
technologies.
accelerated
including
peptide-drug
complexes,
new
vaccines,
innovative
diagnostic
reagents,
has
potential
promote
era
precise
customization
disease
therapeutic
schedule.
Vaccines,
Год журнала:
2025,
Номер
13(3), С. 304 - 304
Опубликована: Март 12, 2025
Respiratory
syncytial
virus
(RSV)
remains
a
significant
global
health
threat,
especially
to
infants,
the
elderly,
and
immunocompromised
individuals.
This
review
comprehensively
explores
progress
in
RSV
vaccine
development,
immune
evaluation
methods,
immunological
surrogate.
The
fusion
(F)
protein,
primary
target
for
has
been
engineered
prefusion
conformation
elicit
potent
neutralizing
antibodies,
while
attachment
(G)
glycoprotein
other
immunogens
are
also
being
explored
broaden
responses.
Advances
diverse
platforms,
ranging
from
live
attenuated
protein
subunit
vaccines
cutting-edge
mRNA-
nanoparticle-based
formulations,
highlight
field’s
progress,
yet
challenges
balancing
safety,
immunogenicity,
durability
persist.
Central
these
efforts
is
identification
validation
of
surrogates,
which
may
serve
as
critical
benchmarks
efficacy.
Neutralizing
antibody
titers,
multifunctional
T
cell
responses,
B
memory
have
emerged
key
correlates
protection.
However,
feasibility
surrogates
depends
on
their
ability
predict
clinical
outcomes
across
populations
settings.
While
antibodies
block
directly,
responses
essential
clearing
infected
cells
preventing
severe
disease,
ensures
long-term
immunity.
Integrating
markers
into
cohesive
framework
requires
standardized
assays,
robust
validation,
an
in-depth
understanding
RSV-induced
response.
Acta Pharmaceutica Sinica B,
Год журнала:
2024,
Номер
14(11), С. 4665 - 4682
Опубликована: Сен. 14, 2024
Aluminum
adjuvants
(Alum),
approved
by
the
US
Food
and
Drug
Administration,
have
been
extensively
used
in
vaccines
containing
recombinant
antigens,
subunits
of
pathogens,
or
toxins
for
almost
a
century.
While
Alums
typically
elicit
strong
humoral
immune
responses,
their
ability
to
induce
cellular
mucosal
immunity
is
limited.
As
an
alternative,
layered
double
hydroxide
(LDH),
widely
antacid,
has
emerged
as
novel
class
potent
nano-aluminum
(NanoAlum),
demonstrating
advantageous
physicochemical
properties,
biocompatibility
adjuvanticity
both
responses.
In
this
review,
we
summarize
compare
advantages
disadvantages
Alum
NanoAlum
these
properties
performance
adjuvants.
Moreover,
propose
key
features
ideal
demonstrate
that
LDH
promising
candidate
summarizing
its
current
progress
immunotherapeutic
cancer
treatments.
Finally,
conclude
review
offering
our
integrated
perspectives
about
remaining
challenges
future
directions
NanoAlum's
application
preclinical/clinical
settings.
Vaccine,
Год журнала:
2024,
Номер
42(10), С. 2530 - 2542
Опубликована: Март 19, 2024
Chinese
Hamster
Ovary
(CHO)
cells,
employed
primarily
for
manufacturing
monoclonal
antibodies
and
other
recombinant
protein
(r-protein)
therapeutics,
are
emerging
as
a
promising
host
vaccine
antigen
production.
This
is
exemplified
by
the
recently
approved
CHO
cell-derived
subunit
vaccines
(SUV)
against
respiratory
syncytial
virus
(RSV)
varicella-zoster
(VZV),
well
enveloped
virus-like
particle
(eVLP)
hepatitis
B
(HBV).
Here,
we
summarize
design,
production,
immunogenicity
features
of
these
review
most
recent
progress
CHO-derived
in
pre-clinical
clinical
development.
We
also
discuss
challenges
associated
with
production
focus
on
ensuring
viral
clearance
eVLP
products.
